• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.

作者信息

Pollyea Daniel A, Raval Aparna, Kusler Brenda, Gotlib Jason R, Alizadeh Ash A, Mitchell Beverly S

出版信息

Hematol Oncol. 2011 Sep;29(3):157-60. doi: 10.1002/hon.976. Epub 2010 Oct 27.

DOI:10.1002/hon.976
PMID:21922510
Abstract
摘要

相似文献

1
Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.TET2突变对接受DNA甲基转移酶抑制剂治疗的骨髓增生异常综合征（MDS）患者mRNA表达及临床结局的影响
Hematol Oncol. 2011 Sep;29(3):157-60. doi: 10.1002/hon.976. Epub 2010 Oct 27.
2
Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.对 355 例 MDS 和 CMML 患者的 TET2 基因进行下一代测序显示，具有早期起源的低丰度突变克隆，但无明确的预后价值。
Blood. 2010 Nov 11;116(19):3923-32. doi: 10.1182/blood-2010-03-274704. Epub 2010 Aug 6.
3
Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.5-羟甲基胞嘧啶水平降低与骨髓增生异常综合征中 TET2 突变和总体生存不良相关。
Leuk Lymphoma. 2013 Nov;54(11):2466-73. doi: 10.3109/10428194.2013.778408. Epub 2013 Mar 27.
4
TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.TET2 突变和高 miR-22 表达作为预测接受低甲基化治疗的骨髓增生异常综合征患者临床结局的生物标志物。
Curr Issues Mol Biol. 2021 Aug 5;43(2):917-931. doi: 10.3390/cimb43020065.
5
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.TET2突变可预测骨髓增生异常综合征患者对去甲基化药物的反应。
Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.
6
Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.骨髓增生异常综合征的CD3⁺和CD34⁺细胞中TET2表达下调并增强CD34⁺细胞增殖。
Int J Clin Exp Pathol. 2015 Sep 1;8(9):10840-6. eCollection 2015.
7
Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.精氨酸酶1的过表达与低级别骨髓增生异常综合征和慢性粒单核细胞白血病中的DNMT3A和TET2突变有关。
Leuk Res. 2018 Feb;65:5-13. doi: 10.1016/j.leukres.2017.12.003. Epub 2017 Dec 6.
8
[TET2 and DLK1 gene expression and their clinical significance in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome].[骨髓增生异常综合征患者骨髓CD(3)(+) T细胞中TET2和DLK1基因表达及其临床意义]
Zhonghua Nei Ke Za Zhi. 2012 Jul;51(7):543-6.
9
Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.在骨髓肿瘤患者中，低水平的十-十一易位蛋白2（TET2）转录本与TET2突变无关。
Diagn Pathol. 2016 Mar 16;11:28. doi: 10.1186/s13000-016-0476-4.
10
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.TET2 突变对低细胞性骨髓增生异常综合征和低原始细胞性急性髓系白血病患者阿扎胞苷治疗反应率的影响。
Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15.

引用本文的文献

1
Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies.线粒体及其与血液系统恶性肿瘤常见基因异常的关系
Life (Basel). 2021 Dec 7;11(12):1351. doi: 10.3390/life11121351.
2
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.基线和连续分子谱分析预测低甲基化剂治疗骨髓增生异常综合征的结果。
Blood Adv. 2021 Feb 23;5(4):1017-1028. doi: 10.1182/bloodadvances.2020003508.
3
Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations.
亚洲人群更易患高危骨髓增生异常综合征，这与其表现出高危细胞遗传学异常的倾向一致。
Cancers (Basel). 2021 Jan 27;13(3):481. doi: 10.3390/cancers13030481.
4
The Impact of DNA Methylation in Hematopoietic Malignancies.DNA甲基化在血液系统恶性肿瘤中的影响
Trends Cancer. 2016 Feb 1;2(2):70-83. doi: 10.1016/j.trecan.2015.12.006.
5
Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.骨髓增生异常综合征的CD3⁺和CD34⁺细胞中TET2表达下调并增强CD34⁺细胞增殖。
Int J Clin Exp Pathol. 2015 Sep 1;8(9):10840-6. eCollection 2015.
6
Digging deep into "dirty" drugs - modulation of the methylation machinery.深入研究“脏”药物——甲基化机制的调控
Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8.
7
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.造血和造血疾病中的十十一易位-2（TET2）基因。
Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13.
8
TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.TET2 突变在 Ph 阴性骨髓增殖性肿瘤中的研究：三种新突变的鉴定及其与临床和实验室发现的关系。
Biomed Res Int. 2013;2013:929840. doi: 10.1155/2013/929840. Epub 2013 May 25.
9
TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significances.骨髓单个核细胞中 TET2 的表达及其在骨髓增生异常综合征患者中的临床意义。
Cancer Biol Med. 2012 Mar;9(1):34-7. doi: 10.3969/j.issn.2095-3941.2012.01.006.
10
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.表观遗传学修饰因子突变在急性髓系白血病发病机制和治疗中的作用。
Blood. 2013 May 2;121(18):3563-72. doi: 10.1182/blood-2013-01-451781.